Cargando…

Cisplatin based chemotherapy in patients with advanced differentiated thyroid carcinoma refractory to I131 treatment

PURPOSE: The purpose of the study was to evaluate the activity and toxicity of cisplatin based chemotherapy in patients with advanced differentiated thyroid cancer refractory to radioactive iodine (I131). PATIENTS AND METHODS: We retrospectively reviewed the records of 20 patients with advanced thyr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hussein, Osama, Karen, Drumea, Zidan, Jamal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932587/ https://www.ncbi.nlm.nih.gov/pubmed/24604949 http://dx.doi.org/10.4103/0971-5851.125233

Ejemplares similares

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
por: Hong, Chae Moon, et al.
Publicado: (2017)

Induction of Leukaemia by (131)I Treatment of Thyroid Carcinoma
por: Brincker, H., et al.
Publicado: (1973)

A phase I study of pazopanib in combination with escalating doses of (131)I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine
por: Chow, Laura Q., et al.
Publicado: (2017)

Unexpected False-positive I-131 Uptake in Patients with Differentiated Thyroid Carcinoma
por: Oral, Aylin, et al.
Publicado: (2018)

Efficacy and Affecting Factors of (131)I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
por: Wang, Chen, et al.
Publicado: (2018)

Analysis of the incidence and influencing factors of hyponatremia before (131)I treatment of differentiated thyroid carcinoma
por: Cao, Jing-Jia, et al.
Publicado: (2021)

Unusual Sites of Metastatic and Benign I 131 Uptake in Patients with Differentiated Thyroid Carcinoma
por: Palaniswamy, Shanmuga S., et al.
Publicado: (2018)

The Value of Pre-Ablative I-131 Scan for Clinical Management in Patients With Differentiated Thyroid Carcinoma
por: van der Boom, Trynke, et al.
Publicado: (2021)

Impact of thyroiditis on (131)I uptake during ablative therapy for differentiated thyroid cancer
por: Lim, Eugenie S, et al.
Publicado: (2019)

I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy
por: Probst, Stephan, et al.
Publicado: (2018)

SAT510 I-131 Therapy with Dosimetry for Advanced Thyroid Carcinoma: Recombinant TSH vs Thyroid Hormone Withdrawal
por: Awad, Dana, et al.
Publicado: (2023)

I(131) Accumulation in Hydrocele in the Setting of Metastatic Papillary Carcinoma Thyroid
por: Seetharam, SJ, et al.
Publicado: (2022)

Advances in Antioxidant Applications for Combating (131)I Side Effects in Thyroid Cancer Treatment
por: Yang, Li, et al.
Publicado: (2023)

Second malignancies in patients with differentiated thyroid carcinoma treated with low and medium activities of radioactive I-131
por: PICIU, DOINA, et al.
Publicado: (2016)

Usefulness of second (131)I treatment in biochemical persistent differentiated thyroid cancer patients
por: Gambale, Carla, et al.
Publicado: (2023)

Anaplastic Variant of Classical Seminoma of the Testis: Northern Israel Oncology Center Experience and Brief Review of Literature
por: Stein, Moshe E., et al.
Publicado: (2014)

Disorders of Dental Hard Tissues Induced by Radioiodine-131 (I-131) Therapy Used in Differentiated Thyroid Cancer: An In Vitro Study
por: Mester, Alexandru, et al.
Publicado: (2020)

FDG PET Predicts the Effects of (131)I and Prognosis for Patients with Bone Metastases from Differentiated Thyroid Carcinoma
por: Wang, Danyang, et al.
Publicado: (2020)

The influence of thionamides on intra-thyroidal uptake of (131)I during radioiodine-131 treatment of Graves’ disease
por: Happel, Christian, et al.
Publicado: (2023)

Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer
por: Gao, Haiyan, et al.
Publicado: (2023)

Rate of thyroglossal duct remnant visualization after total thyroidectomy for differentiated thyroid carcinoma and its impact on clinical outcome of radioactive iodine (I-131) ablation
por: Mohamed Sayed, Mohamed Hosny, et al.
Publicado: (2015)

MON-559 Inappropriate Dosing of I-131 in Non-Metastatic Differentiated Thyroid Cancer
por: Alzenaidi, Ahlam, et al.
Publicado: (2019)

Effect of (131)I Therapy on Complete Blood Count in Patients with Differentiated Thyroid Cancer
por: Rui, Zhongying, et al.
Publicado: (2021)

Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for (131)I Administration
por: Gomes-Lima, Cristiane J, et al.
Publicado: (2022)

I-131 Avid Tumor Thrombus in a Case of Poorly Differentiated Thyroid Cancer
por: Gill, Sana Munir, et al.
Publicado: (2023)

Outcomes following I-131 treatment with cumulative dose exceeding or equal to 600 mCi in differentiated thyroid carcinoma patients
por: Kaewput, Chalermrat, et al.
Publicado: (2020)

HSA-MnO(2)-(131)I Combined Imaging and Treatment of Anaplastic Thyroid Carcinoma
por: Yan, Ziyu, et al.
Publicado: (2022)

The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma
por: Zhang, Haiying, et al.
Publicado: (2014)

Thyroid hormone replacement one day before (131)I therapy in patients with well-differentiated thyroid cancer
por: Kayano, Daiki, et al.
Publicado: (2013)

The clinical significance of remnant thyroid tissue in thyroidectomized differentiated thyroid cancer patients on (131)I-SPECT/CT
por: Wang, Feng, et al.
Publicado: (2021)

Global Hotspots and Prospects of I-131 Therapy in Thyroid Carcinoma via Bibliometric Analysis
por: Lin, Shang, et al.
Publicado: (2021)

Gut microbiota is associated with response to (131)I therapy in patients with papillary thyroid carcinoma
por: Zheng, Lei, et al.
Publicado: (2022)

DIFFERENTIATED THYROID CANCER IN PEDIATRIC POPULATION (≤18 YEARS): POSTOPERATIVE TREATMENT WITH RADIOACTIVE IODINE (I-131)
por: Prpić, Marin, et al.
Publicado: (2019)

Empiric Therapy with Low-Dose I-131 in Differentiated Cancer Thyroid: What is the Magic Number?
por: Shinto, Ajit S., et al.
Publicado: (2013)

Efficacy of Dosimetric Versus Empiric Prescribed Activity of (131)I for Therapy of Differentiated Thyroid Cancer
por: Klubo-Gwiezdzinska, Joanna, et al.
Publicado: (2011)

Dosimetry during adjuvant (131)I therapy in patients with differentiated thyroid cancer-clinical implications
por: Szumowski, Piotr, et al.
Publicado: (2021)

Clinical Analysis of the Short-Term Outcome of Papillary Thyroid Micro Carcinoma After (131)I Treatment
por: Cao, Jingjia, et al.
Publicado: (2021)

Transcriptional response to (131)I exposure of rat thyroid gland
por: Rudqvist, Nils, et al.
Publicado: (2017)

Effect of (131)I ‘clear residual thyroid tissue’ after surgery on the function of parathyroid gland in differentiated thyroid cancer
por: ZHAO, ZHI-HUA, et al.
Publicado: (2015)

Platinum-based Chemotherapy in Primary Advanced Seminoma—a Retrospective Analysis: Treatment Results at the Northern Israel Oncology Center (1989–2010)
por: Stein, Moshe E., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_75hr545a077lat3cmn4hb834t4